NCT04248231View on ClinicalTrials.gov

CINSARC Genomic Signature as Predictor of Resectability of Ovarian Adenocarcinoma

CompletedOBSERVATIONAL
Enrollment

150

Participants

Timeline

Start Date

September 15, 2019

Primary Completion Date

September 15, 2020

Study Completion Date

December 23, 2021

Conditions
Ovarian Adenocarcinoma
Interventions
OTHER

CINSARC signature

CINSARC molecular signature analysis

Trial Locations (1)

31059

Institut Claudius Regaud Institut Universitaire du cancer Toulouse Oncopole, Toulouse

All Listed Sponsors
lead

Institut Claudius Regaud

OTHER

NCT04248231 - CINSARC Genomic Signature as Predictor of Resectability of Ovarian Adenocarcinoma | Biotech Hunter | Biotech Hunter